ANI launches generic aminocaproic acid

ANI is introducing aminocaproic acid tablets in a dosage strength of 500 mg, following approval by the Food and Drug Administration.

Aminocaproic acid tablets have a market value of approximately $12.7 million, according to IQVIA.

"This is ANI’s seventh generic product launch in 2020 and reaffirms our commitment to increasing the pace of market introductions for our products. This important therapeutic is one of the pipeline generic products we acquired from Amerigen Pharmaceuticals earlier this year. I congratulate our team on this achievement and look forward to additional ANI product launches in the near future, as we focus on realizing the full potential of our product portfolio,” said Nikhil Lalwani, president and CEO.

Aminocaproic acid tablets are useful in enhancing hemostasis when fibrinolysis contributes to bleeding. In life-threatening situations, transfusion of appropriate blood products and other emergency measures may be required.